CRMD

CorMedix Inc. NASDAQ Listed May 13, 2010

Healthcare ·Biotechnology ·US · cormedix.com

$7.87

Mkt Cap $616.9M

52w Low $6.13 15.4% of range 52w High $17.43

50d MA $7.05 200d MA $9.80

P/E (TTM) 3.5x

EV/EBITDA 5.1x

P/B 1.4x

Debt/Equity 0.4x

ROE 40.2%

P/FCF 4.8x

RSI (14) —

ATR (14) —

Beta 1.41

50d MA $7.05

200d MA $9.80

Avg Volume 1.4M

About

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requ…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	AMC	0.86	0.61	-29.1%	6.30	+0.2%	+2.5%	+4.1%	+6.7%	+6.2%	+1.6%	—
Nov 12, 2025	AMC	0.48	0.57	+18.8%	11.42	+0.0%	-1.8%	-1.6%	-12.6%	-11.8%	-12.2%	—
Aug 7, 2025	AMC	0.20	0.28	+40.0%	10.81	-1.7%	-4.4%	-6.8%	+6.4%	+11.7%	+16.7%	—
May 6, 2025	AMC	0.25	0.30	+20.0%	11.16	-0.6%	+4.7%	+7.8%	+4.5%	+6.3%	+4.2%	—
Mar 25, 2025	AMC	0.17	0.22	+29.4%	7.34	+1.6%	-2.5%	-8.6%	-8.2%	-16.1%	-17.3%	—
Oct 30, 2024	AMC	-0.10	-0.05	+50.0%	10.05	-0.6%	+0.1%	-0.6%	-4.6%	+1.0%	+2.7%	—
Aug 14, 2024	AMC	-0.26	-0.25	+3.8%	4.92	+0.2%	-2.4%	-2.2%	+4.9%	+2.0%	+1.8%	—
May 9, 2024	AMC	-0.27	-0.25	+7.4%	5.41	-0.2%	-4.4%	-2.0%	-1.5%	-3.0%	-3.9%	—
Mar 12, 2024	AMC	-0.21	-0.26	-23.8%	3.42	+1.5%	+14.0%	+22.2%	+11.4%	+11.1%	+12.0%	—
Nov 14, 2023	AMC	-0.21	-0.17	+19.0%	3.13	+17.3%	+6.4%	+21.4%	+28.1%	+20.8%	+15.7%	—
Aug 8, 2023	AMC	-0.22	-0.25	-13.6%	4.42	-0.9%	-1.6%	-0.5%	-0.5%	-6.3%	-3.6%	—
May 15, 2023	AMC	-0.20	-0.24	-20.0%	5.15	-3.7%	-13.4%	-15.0%	-13.8%	-1.0%	-0.4%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 28	Leerink Partners	Maintains	Outperform → Outperform	—	$7.82	$7.89	+0.9%	-3.2%	-4.3%	-2.9%	-0.4%	—
Apr 28	RBC Capital	Maintains	Outperform → Outperform	—	$7.82	$7.89	+0.9%	-3.2%	-4.3%	-2.9%	-0.4%	—
Apr 28	Citizens	Maintains	Market Outperform → Market Outperform	—	$7.82	$7.89	+0.9%	-3.2%	-4.3%	-2.9%	-0.4%	—
Apr 27	Needham	Maintains	Buy → Buy	—	$7.42	$7.53	+1.5%	+5.4%	+2.0%	+0.8%	+2.3%	+5.0%
Apr 27	D. Boral Capital	Maintains	Buy → Buy	—	$7.42	$7.53	+1.5%	+5.4%	+2.0%	+0.8%	+2.3%	+5.0%
Mar 5	Needham	Maintains	Buy → Buy	—	$7.12	$6.35	-10.8%	-11.5%	-9.3%	-7.9%	-5.6%	-6.0%
Feb 11	D. Boral Capital	Maintains	Buy → Buy	—	$7.69	$7.77	+1.0%	-3.4%	-4.3%	-4.6%	-6.2%	-6.8%
Jan 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.44	$7.36	-1.1%	-2.3%	+4.3%	+4.2%	+4.2%	+7.8%
Jan 21	RBC Capital	Maintains	Outperform → Outperform	—	$6.88	$6.88	+0.0%	+6.5%	+8.1%	+5.7%	+12.8%	+12.6%
Jan 8	Needham	Maintains	Buy → Buy	—	$11.17	$8.74	-21.8%	-32.8%	-31.7%	-36.0%	-36.8%	-36.5%
Jan 8	D. Boral Capital	Maintains	Buy → Buy	—	$11.17	$8.74	-21.8%	-32.8%	-31.7%	-36.0%	-36.8%	-36.5%
Dec 18	D. Boral Capital	Maintains	Buy → Buy	—	$11.45	$11.57	+1.0%	+4.1%	+5.0%	+8.2%	+4.6%	+6.5%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.42	$11.42	+0.0%	-1.8%	-1.6%	-12.6%	-11.8%	-12.2%
Nov 12	Needham	Maintains	Buy → Buy	—	$11.19	$11.74	+4.9%	+2.1%	+0.2%	+0.4%	-10.8%	-10.0%
Nov 12	D. Boral Capital	Maintains	Buy → Buy	—	$11.19	$11.74	+4.9%	+2.1%	+0.2%	+0.4%	-10.8%	-10.0%
Oct 21	RBC Capital	Maintains	Outperform → Outperform	—	$12.16	$12.25	+0.7%	-4.2%	-7.9%	-7.0%	-8.1%	-9.1%
Oct 20	D. Boral Capital	Upgrade	Hold → Buy	—	$10.18	$11.78	+15.7%	+19.4%	+14.4%	+10.0%	+11.1%	+9.7%
Sep 9	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$12.75	$12.93	+1.4%	+2.2%	+0.3%	+2.7%	+1.5%	-0.8%
Aug 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.81	$10.63	-1.7%	-4.4%	-6.8%	+6.4%	+11.7%	+16.7%
Jun 30	D. Boral Capital	Downgrade	Buy → Hold	—	$12.50	$12.64	+1.1%	-1.4%	-5.7%	-7.3%	-7.0%	-8.6%
Jun 24	Needham	Maintains	Buy → Buy	—	$16.56	$16.89	+2.0%	-5.1%	-9.6%	-9.7%	-24.5%	-25.6%
Jun 23	D. Boral Capital	Maintains	Buy → Buy	—	$13.61	$16.74	+23.0%	+21.7%	+15.5%	+10.0%	+9.9%	-8.2%
Jun 20	RBC Capital	Maintains	Outperform → Outperform	—	$13.58	$13.87	+2.1%	+0.2%	+21.9%	+15.8%	+10.2%	+10.2%
May 7	Needham	Maintains	Buy → Buy	—	$11.16	$11.09	-0.6%	+4.7%	+7.8%	+4.5%	+6.3%	+4.2%
May 6	D. Boral Capital	Maintains	Buy → Buy	—	$9.03	$9.59	+6.2%	+23.6%	+29.3%	+33.2%	+29.1%	+31.3%
Apr 9	Needham	Maintains	Buy → Buy	—	$6.79	$6.59	-2.9%	+3.1%	+0.7%	+1.8%	+5.0%	+9.0%
Apr 8	D. Boral Capital	Maintains	Buy → Buy	—	$6.07	$7.51	+23.7%	+11.9%	+15.3%	+12.7%	+13.8%	+17.5%
Mar 26	RBC Capital	Maintains	Outperform → Outperform	—	$7.34	$7.46	+1.6%	-2.5%	-8.6%	-8.2%	-16.1%	-17.3%
Mar 26	Needham	Maintains	Buy → Buy	—	$7.34	$7.46	+1.6%	-2.5%	-8.6%	-8.2%	-16.1%	-17.3%
Mar 25	D. Boral Capital	Maintains	Buy → Buy	—	$10.77	$8.69	-19.3%	-31.8%	-33.5%	-37.7%	-37.4%	-42.8%
Mar 5	D. Boral Capital	Maintains	Buy → Buy	—	$9.85	$9.74	-1.1%	+2.6%	-3.7%	+8.7%	+8.9%	+7.5%
Jan 22	D. Boral Capital	Maintains	Buy → Buy	—	$12.49	$12.50	+0.1%	-1.5%	-1.5%	-0.6%	-0.9%	-2.6%
Dec 19	RBC Capital	Maintains	Outperform → Outperform	—	$8.12	$8.44	+3.9%	+9.2%	+5.5%	+3.7%	+2.6%	+4.7%
Oct 31	Needham	Maintains	Buy → Buy	—	$10.05	$9.99	-0.6%	+0.1%	-0.6%	-4.6%	+1.0%	+2.7%
Aug 15	RBC Capital	Maintains	Outperform → Outperform	—	$4.92	$4.93	+0.2%	-2.4%	-2.2%	+4.9%	+2.0%	+1.8%
Aug 15	Needham	Maintains	Buy → Buy	—	$4.92	$4.93	+0.2%	-2.4%	-2.2%	+4.9%	+2.0%	+1.8%
Jul 25	Truist	Maintains	Buy → Buy	—	$4.77	$4.74	-0.6%	-1.3%	-4.8%	-1.9%	-5.2%	-4.0%
Jun 19	Needham	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
May 13	Needham	Maintains	Buy → Buy	—	$5.17	$5.13	-0.8%	+2.5%	+3.1%	+1.5%	+0.6%	-1.0%
Apr 9	Needham	Maintains	Buy → Buy	—	$4.76	$4.85	+1.9%	-0.2%	+10.9%	+34.2%	+22.7%	+13.0%
Apr 9	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$4.76	$4.85	+1.9%	-0.2%	+10.9%	+34.2%	+22.7%	+13.0%
Mar 13	RBC Capital	Maintains	Outperform → Outperform	—	$3.42	$3.47	+1.5%	+14.0%	+22.2%	+11.4%	+11.1%	+12.0%
Mar 12	Needham	Maintains	Buy → Buy	—	$3.52	$3.43	-2.6%	-2.8%	+10.8%	+18.8%	+8.2%	+8.0%
Jan 31	Truist	Maintains	Buy → Buy	—	$3.14	$3.15	+0.3%	-6.1%	-3.2%	-1.3%	-5.1%	-5.7%
Nov 15	RBC Capital	Maintains	Outperform → Outperform	—	$3.13	$3.67	+17.3%	+6.4%	+21.4%	+28.1%	+20.8%	+15.7%
Nov 15	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$3.13	$3.67	+17.3%	+6.4%	+21.4%	+28.1%	+20.8%	+15.7%
Nov 15	Truist	Maintains	Buy → Buy	—	$3.13	$3.67	+17.3%	+6.4%	+21.4%	+28.1%	+20.8%	+15.7%
Nov 15	Needham	Maintains	Buy → Buy	—	$3.13	$3.67	+17.3%	+6.4%	+21.4%	+28.1%	+20.8%	+15.7%
Aug 8	Needham	Maintains	Buy → Buy	—	$4.10	$4.10	+0.0%	+7.8%	+6.1%	+7.3%	+7.3%	+1.0%
Jun 21	Needham	Maintains	Buy → Buy	—	$5.49	$5.60	+2.0%	+5.6%	+3.6%	-0.2%	-11.3%	-9.5%

Recent Filings

8-K · 7.01 ! Medium

CorMedix Inc. -- 8-K 7.01: Regulation FD Disclosure

CorMedix announced positive Phase III topline data for REZZAYO (rezafungin) in fungal infection prophylaxis, potentially supporting regulatory approval and commercialization of this antifungal candidate.

Apr 27

8-K · 7.01 ! Medium

CorMedix Inc. -- 8-K 7.01: Regulation FD Disclosure

CorMedix reaffirmed its 2027 DefenCath sales guidance of $100-$140 million, correcting an inadvertent $100-$125 million range cited on its March earnings call.

Mar 6

8-K

CorMedix Inc. -- 8-K Filing

CorMedix reported strong 2025 results with $401.3 million pro forma annual revenue and $14.0 million net income in Q4, demonstrating profitability and solid financial performance.

Mar 5

Data updated apr 25, 2026 3:16am · Source: massive.com